Table 1:

Patient Characteristics

	(n=16)
Age
median age (range)	54 (30-68)
Sex, n (%)
Female	4 (25)
Male	12 (75)
Diagnosis, n (%)
Acute myeloid leukemia	6 (38)
Non Hodgkin Lymphoma	4 (25)
Multiple Myeloma	2 (13)
Hodgkin lymphoma	1 (6)
Chronic Lymphocytic Leukemia	1 (6)
Myelofibrosis	1 (6)
MDS/MPN (CMML vs CML)	1 (6)
Allo-Transplant Overall Disease Risk Index, n (%) [12]
Low	2 (13)
Intermediate	9 (56)
High	5 (31)
Very High	0 (0)
CMV status, n (%)
Recipient or donor positive	12 (75)
Recipient and donor negative	4 (25)
Conditioning Regimens, n (%)
Fludarabine melphalan alemtuzumab	12 (75)
Busulfan, fludarabine, antithymocyte globulin	3 (19)
Busulfan, cyclophosphamide, antithymocyte globulin	1 (6)
GvHD prophylaxis at the time of study DLI infusion, n (%)
Mycophenolate Mofetil alone	7 (44)
Prednisone alone	2 (12)
Tacrolimus alone	1 (6)
Two of Mycophenolate Mofetil, prednisone and tacrolimus	3 (19)
None	3 (19)